Publication
Title
Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, and MRS, and clinical and cognitive testing
Author
Abstract
Background/objectives Fluoxetine and prucalopride might change phosphocreatine (PCr) levels via the cAMP-PKA pathway, an interesting target in the neurodegenerative mechanisms of MS. Methods We conducted a two-center double-blind, placebo-controlled, randomized trial including 48 relapsing-remitting MS patients. Patients were randomized to receive placebo (n = 13), fluoxetine (n = 15), or prucalopride (n = 14) for 6 weeks. Proton (H-1) and phosphorus (P-31) magnetic resonance spectroscopy (MRS) as well as volumetric and perfusion MR imaging were performed at weeks 0, 2, and 6. Clinical and cognitive testing were evaluated at weeks 0 and 6. Results No significant changes were observed for both P-31 and H-1 MRS indices. We found a significant effect on white matter volume and a trend towards an increase in grey matter and whole brain volume in the fluoxetine group at week 2; however, these effects were not sustained at week 6 for white matter and whole brain volume. Fluoxetine and prucalopride showed a positive effect on 9-HPT, depression, and fatigue scores. Conclusion Both fluoxetine and prucalopride had a symptomatic effect on upper limb function, fatigue, and depression, but this should be interpreted with caution. No effect of treatment was found on P-31 and H-1 MRS parameters, suggesting that these molecules do not influence the PCr metabolism.
Language
English
Source (journal)
Journal of neurology. - Berlin
Publication
Berlin : 2018
ISSN
0340-5354
0012-1037
Volume/pages
265 :11 (2018) , p. 2614-2624
ISI
000448450200013
Pubmed ID
30187159
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 10.12.2018
Last edited 15.10.2021
To cite this reference